Neurosense Therapeutics is trading at $0.49, up +5.08% in pre-market; the catalyst remains unclear and may reflect low-priced biotech trading activity.
- No confirmed company-specific announcement was identified for August 13, 2026.
- The latest notable update, on August 6, concerned PrimeC’s planned December 2026 Health Canada filing, but it does not directly explain this move.
- Broader U.S. futures were only modestly higher, offering limited support for a global explanation.